JP2023528207A - 組換えｃｄ４０結合タンパク質及びそれらの使用 - Google Patents

組換えｃｄ４０結合タンパク質及びそれらの使用 Download PDF

Info

Publication number
JP2023528207A
JP2023528207A JP2022568692A JP2022568692A JP2023528207A JP 2023528207 A JP2023528207 A JP 2023528207A JP 2022568692 A JP2022568692 A JP 2022568692A JP 2022568692 A JP2022568692 A JP 2022568692A JP 2023528207 A JP2023528207 A JP 2023528207A
Authority
JP
Japan
Prior art keywords
seq
ankyrin repeat
amino acid
acid sequence
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528207A5 (https=
Inventor
ヴァレリー ペリーヌ カラブロ
ニコロ リガモンティ
クララ ドンケ
アーニャ クリスティーナ シュレーゲル
Original Assignee
モレキュラー パートナーズ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー パートナーズ アクチェンゲゼルシャフト filed Critical モレキュラー パートナーズ アクチェンゲゼルシャフト
Publication of JP2023528207A publication Critical patent/JP2023528207A/ja
Publication of JP2023528207A5 publication Critical patent/JP2023528207A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022568692A 2020-05-14 2021-05-14 組換えｃｄ４０結合タンパク質及びそれらの使用 Pending JP2023528207A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20174830.8 2020-05-14
EP20174830 2020-05-14
PCT/EP2021/062874 WO2021229076A1 (en) 2020-05-14 2021-05-14 Recombinant cd40 binding proteins and their use

Publications (2)

Publication Number Publication Date
JP2023528207A true JP2023528207A (ja) 2023-07-04
JP2023528207A5 JP2023528207A5 (https=) 2024-05-09

Family

ID=70738293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568692A Pending JP2023528207A (ja) 2020-05-14 2021-05-14 組換えｃｄ４０結合タンパク質及びそれらの使用

Country Status (7)

Country Link
US (1) US20240279309A1 (https=)
EP (1) EP4149960A1 (https=)
JP (1) JP2023528207A (https=)
CN (1) CN115996945A (https=)
AU (1) AU2021271131A1 (https=)
CA (1) CA3178478A1 (https=)
WO (1) WO2021229076A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
EP4137508A1 (en) * 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
WO2023021050A1 (en) * 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
WO2024251695A1 (en) * 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd47 binding proteins and their use
WO2025146490A1 (en) * 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
PL2643349T3 (pl) * 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN105209483B (zh) * 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
KR102427117B1 (ko) * 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
CN109790206A (zh) * 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FIEDLER, ULRIKE ET AL.: ""Abstract 4552: Tumor-restricted immune modulation by multispecific molecules from the DARPin toolb", CANCER RESEARCH, vol. Vol. 78, No. 13_Supplement, JPN6025017554, 2018, pages 4552 - 4552, ISSN: 0005587412 *
LEVITSKY, VICTOR ET AL.: ""Abstract B026: Development of tumor-targeted agonistic Immunomodulators using the DARPin technolog", CANCER IMMUNOLOGY RESEARCH, vol. 7, JPN6025017552, 2019, pages 026 - 026, ISSN: 0005587411 *
LI, JUNAN ET AL.: ""Ankyrin Repeat: A Unique Motif Mediating Protein−Protein Interactions"", BIOCHEMISTRY, vol. 45, no. 51, JPN6025017551, 2006, pages 15168 - 15178, ISSN: 0005587413 *
RIGAMONTI, NICOLO ET AL.: ""Abstract 3251: Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPinmole", CANCER RESEARCH, vol. Vol. 79, No. 13_Supplement, JPN6025017553, 2019, pages 3251 - 3251, ISSN: 0005587410 *

Also Published As

Publication number Publication date
WO2021229076A1 (en) 2021-11-18
US20240279309A1 (en) 2024-08-22
EP4149960A1 (en) 2023-03-22
AU2021271131A1 (en) 2022-12-15
CA3178478A1 (en) 2021-11-18
CN115996945A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
JP2023528207A (ja) 組換えｃｄ４０結合タンパク質及びそれらの使用
JP7611173B2 (ja) 組換えｆａｐ結合タンパク質及びそれらの使用
CA2892747C (en) Binding proteins comprising at least two repeat domains against her2.
AU2016295024B2 (en) Her2 binding proteins based on di-ubiquitin muteins
JP2019531093A (ja) 組み換え結合タンパク質及びその使用
CN114222757A (zh) 重组4-1bb结合蛋白及其用途
US20250074994A1 (en) Novel darpin based cd70 engagers
US20240317852A1 (en) Novel darpin based cd33 engagers
EP3253785A1 (en) Novel egfr binding proteins
JP2024509241A (ja) 新規のＤＡＲＰｉｎに基づくＣＤ１２３エンゲージャ
EP4724473A1 (en) Recombinant cd47 binding proteins and their use
RU2778346C2 (ru) Рекомбинантные связывающие белки и их применение
CN121263440A (zh) 重组cd2结合蛋白及其用途
CN117242100A (zh) 基于DARPin的新型CD70接合物
EP3325514A1 (en) Her2 binding proteins based on di-ubiquitin muteins
EP3325515A1 (en) Novel binding proteins based on di-ubiquitin muteins and methods for generation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104